Daewoong Pharmaceutical Co., Ltd.

-Attracts Over 200 Aesthetic Experts from Six Middle Eastern Countries 

-Leading KOLs from Korea and the Middle East Deliver Anatomy-Based Education, Live Demonstrations, and Case Sharing

-Dr. Azzam Alkhalifah: "Nabota Is Establishing Itself as a Trusted Toxin in the Middle East"

SEOUL, South Korea, Dec. 3, 2025 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Shawn Park and Chang-jae Lee) announced on the 1st that it successfully held the Nabota Master Class (NMC) Middle East & North Africa (MENA) from Nobember 28 for two days in Jeddah, Saudi Arabia. This marks the first time NMC has been held outside Korea, drawing more than 200 medical professionals from six major Middle Eastern countries including Saudi Arabia, the UAE, and Qatar.

To date, Nabota has expanded into 10 countries in the Middle East—more markets than any other Korean toxin brand—achieving rapid growth in key markets such as Saudi Arabia and the UAE. In Saudi Arabia, the largest aesthetic market in the region, Nabota has continued to gain market share since its launch, solidifying its presence through consistent clinical performance.

As demand for botulinum toxin continues to rise among younger consumers in the Middle East, Daewoong Pharmaceutical has been strengthening its training infrastructure by offering structured physician education and academic support. Through these efforts, the company aims to enhance treatment proficiency, improve patient satisfaction, and build a sustainable win–win–win model for physicians, patients, and the company.

The NMC MENA program featured top aesthetic, plastic surgery, and anatomy experts from Korea and the Middle East, receiving strong engagement from attendees. Key sessions included:

A facial anatomy lecture by Professor Seung-Ho Han (Ewha Womans University), focused on improving the safety and precision of toxin injections;

A protocol-based training session by Dr. Je-young Park (Chief Director, Apgujeong Oracle Dermatology), presenting clinical applications and standardized techniques for specialized procedures such as NABOLIFT and NABOGLOW;

Hands-on sessions led by Dr. Jee-soo Kook (It's Me Clinic) and eight additional expert faculty members.

In addition, prominent Middle Eastern KOLs—including Dr. Abdulkader Ramo, Dr. Azzam Alkhalifah, Professor Amir Mrad (Alfaisal University), and Dr. Carmelo Crisafulli—shared real-world Nabota treatment cases and engaged in in-depth panel discussions on dilution methods, diffusion characteristics, and clinical differentiators of the product.

Dr. Alkhalifah stated, "Nabota is becoming a trusted botulinum toxin brand in the Middle East based on its consistent clinical outcomes. This event was particularly meaningful as it allowed us to deeply explore Nabota's clinical advantages and standardized injection protocols in one comprehensive program."

Daewoong Pharmaceutical has expanded NMC from two to four annual global sessions beginning this year, operating tailored academic programs across Asia, Latin America, and the Middle East. The company aims to evolve the platform beyond simple injection workshops into a global education ecosystem that strengthens clinical expertise, fosters scientific exchange, and enhances brand credibility.

Jun-soo Yun, Head of Daewoong Pharmaceutical's Nabota Business Division, commented, "NMC MENA was more than a training event—it was a milestone moment where we and our Middle Eastern partners collectively established new standards in aesthetic medicine. We will continue to expand global academic networks and reinforce Nabota's position as a trusted global toxin brand through evidence-based education and continuous clinical collaboration."

Photo - https://mma.prnewswire.com/media/2837143/image.jpg 

Logo - https://mma.prnewswire.com/media/1676530/Daewoong_Pharmaceuticals_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/daewoong-pharmaceutical-holds-nabota-master-class-in-saudi-arabia-302631183.html

• Third Independent Data Monitoring Committee (IDMC) review confirms safety and continuation of the study
• 94 patients enrolled out of 102 planned across Korea and the U.S. 
• Interim baseline characteristics to be presented at the 2025 KATRD International Conference

SEOUL, South Korea, Oct. 27, 2025 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seong-Soo Park and Chang-Jae Lee) announced that its first-in-class idiopathic pulmonary fibrosis (IPF) drug candidate Bersiporocin (DWN12088) received a recommendation to continue its global Phase 2 clinical trial following a positive safety review by the third Independent Data Monitoring Committee (IDMC) held on September 23.

The IDMC conducted an in-depth evaluation of interim safety data from 89 enrolled patients and found no significant safety concerns that would impact the trial's continuation. To date, Daewoong has enrolled 94 participants, representing approximately 92% of the target population (102 patients), and the study is progressing as planned.

The ongoing Phase 2 trial (ClinicalTrials.gov Identifier: NCT05389215) aims to evaluate the safety, tolerability, and efficacy of Bersiporocin as monotherapy or in combination with approved antifibrotic drugs (nintedanib or pirfenidone) in patients aged 40 years and older.

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by abnormal collagen accumulation leading to irreversible loss of lung function. Currently available treatments can only slow disease progression, highlighting the unmet medical need for novel therapies that address the root cause of fibrosis.

Bersiporocin is a first-in-class, orally administered antifibrotic therapy that selectively inhibits prolyl-tRNA synthetase (PRS) — a key enzyme involved in collagen synthesis. By directly blocking this pathway, Bersiporocin is designed to halt fibrosis at its origin, potentially overcoming the limitations of existing antifibrotic treatments. The trial is being conducted at major clinical sites in South Korea and the United States. Trial information is available at ClinicalTrials.gov (NCT05389215) and the Pulmonary Fibrosis Foundation (PFF) clinical registry.

Professor Jin Woo Song of Asan Medical Center, who serves as the Coordinating Investigator and Principal Investigator of the global Phase 2 study, will present on October 30 a poster at the 2025 KATRD International Conference (Korean Academy of Tuberculosis and Respiratory Diseases, October 29–31) featuring the interim analysis of baseline characteristics from 92 enrolled patients. The findings demonstrate consistency in key demographic and functional characteristics and treatment patterns between Korean and U.S. cohorts, supporting the applicability of the trial design across diverse populations and providing a foundation for interpreting future efficacy outcomes.

"This third IDMC recommendation represents a major milestone reaffirming the safety and progress of Bersiporocin," said Seong-Soo Park, CEO of Daewoong Pharmaceutical. "We will continue to advance the Phase 2 study to deliver a new and effective treatment option for patients suffering from idiopathic pulmonary fibrosis worldwide."

View original content to download multimedia:https://www.prnewswire.com/news-releases/daewoong-pharmaceutical-third-idmc-reaffirms-safety-of-bersiporocin-and-recommends-continuation-of-global-phase-2-clinical-trial-302595005.html

SOURCE Daewoong Pharmaceutical Co., Ltd.